

A Phase 1 trial: MEU Phase 1 Clinic: SUDO-286-102

Submission date 05/09/2025	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 08/09/2025	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 27/04/2026	Condition category Other	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr Naimat Khan

Contact details

The Langley Building
Wythenshawe Hospital
Manchester
United Kingdom
M23 9QZ
+44 (0)161 946 4050
MKhan@meu.org.uk

Type(s)

Public, Scientific

Contact name

Dr Ian Mills

Contact details

Sudo Biosciences Limited, 3rd Floor, 1 Ashley Road
Altrincham
United Kingdom

WA14 2DT

-

imills@sudobio.com

Additional identifiers

Integrated Research Application System (IRAS)

1006866

Study information

Scientific Title

A Phase 1 trial: MEU Phase 1 Clinic: SUDO-286-102

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 20/06/2024, North West - Greater Manchester Central Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 2071048023; gmcentral.rec@hra.nhs.uk), ref: 24/NW/0062

Study design

Interventional single-centre blinded randomized study

Primary study design

Other

Study type(s)

Safety

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Other

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

17/04/2025

Eligibility

Key inclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer, Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

0

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

20/06/2024

Date of final enrolment

18/12/2024

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Medicines Evaluation Unit Limited
The Langley Building
Southmoor Road
Wythenshawe
Manchester
England
M23 9QZ

Sponsor information

Organisation
Sudo Biosciences

Funder(s)

Funder type
Industry

Funder Name
Sudo Biosciences

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not expected to be made available